Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.47 |
| ▸ | EED | O75530 | 2/20 | 0.44 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.44 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.44 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.44 |
| ▸ | PDE9A | O76083 | 2/20 | 0.40 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.40 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12498796 | 0.89 | EZH2 (0.62) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684232 | 0.84 | EZH2 (0.63) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL19391619 | 0.81 | EZH2 (0.55) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12683918 | 0.81 | EZH2 (0.62) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12683912 | 0.81 | EZH2 (0.68) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL15492830 | 0.80 | EZH2 (0.62) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684233 | 0.80 | EZH2 (0.62) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684194 | 0.80 | EZH2 (0.67) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL19391595 | 0.79 | EZH2 (0.51) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL21418328 | 0.79 | EZH2 (0.46) | EZH2EEDRBBP4SUZ12RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317643-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317643-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | EZH2 1355/4885EED 2585/4885RBBP4 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.